Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Abstract

Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).

Keywords

Chimeric antigen receptorCD19Natural killer T cellNatural killer cellCancer researchLymphokine-activated killer cellImmunologyCellBiologyAntigenInterleukin 21ImmunotherapyT cellImmune systemCytotoxic T cellIn vitroGenetics

MeSH Terms

AgedAllograftsAntigensCD19Cell- and Tissue-Based TherapyFemaleFetal BloodGenetic VectorsHumansKiller CellsNaturalLeukemiaLymphocyticChronicB-CellLymphomaNon-HodgkinMaleMiddle AgedReceptorsChimeric AntigenRemission InductionRetroviridaeTransplantation Conditioning

Affiliated Institutions

The University of Texas MD Anderson Cancer Center US

Related Publications

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster , Michael Bishop , Constantine S. Tam +21 more

In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use o...

2018 New England Journal of Medicine 3775 citations

Cancer immunotherapy using checkpoint blockade

Antoni Ribas , Jedd D. Wolchok

The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...

2018 Science 6236 citations

The biologic importance of tumor‐infiltrating lymphocytes

F. Stephen Hodi , Glenn Dranoff

Detailed pathologic analysis has delineated a close association between intratumoral CD 8 + cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the...

2010 Journal of Cutaneous Pathology 55 citations

Human embryonic stem cell–derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential

Maxim A. Vodyanik , Jack A. Bork , James A. Thomson +1 more

Abstract Embryonic stem (ES) cells have the potential to serve as an alternative source of hematopoietic precursors for transplantation and for the study of hematopoietic cell d...

2004 Blood 599 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi , Steven O’Day , David F. McDermott +26 more

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse eve...

2010 New England Journal of Medicine 14794 citations

Publication Info

Year: 2020
Type: article
Volume: 382
Issue: 6
Pages: 545-553
Citations: 1930
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1930

OpenAlex

111

Influential

1781

CrossRef

Cite This

APA Style

                            
                                
                                    Enli Liu, 
                                
                                    David Marín, 
                                
                                    Pinaki P. Banerjee
                                
                                et al.
                            
                            (2020). 
                            Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. 
                            New England Journal of Medicine
                            , 382
                            (6)
                            , 545-553.
                            https://doi.org/10.1056/nejmoa1910607
                        

Identifiers

DOI: 10.1056/nejmoa1910607
PMID: 32023374
PMCID: PMC7101242

Data Quality

Data completeness: 90%